Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?


OverviewRevenueFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary


Brainstorm Cell Therapeutics is owned by 15.20% institutional investors, 9.04% insiders, and 75.76% retail investors. Armistice capital is the largest institutional shareholder, holding 12.23% of BCLI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 0.89% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics15.20%9.04%75.76%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Armistice capital7.92M12.23%$2.68M
Vanguard group1.51M2.33%$511.35K
Geode capital management484.29K0.75%$163.99K
Blackrock386.41K0.60%$130.80K
Liberty wealth management340.15K0.53%$115.00K
Weaver consulting group15.62K0.29%$35.46K
State street117.26K0.18%$39.69K
Northern trust112.36K0.17%$38.03K
Raymond james & associates111.28K0.17%$37.67K
Two sigma securities102.02K0.16%$34.53K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Armistice capital7.92M0.03%$2.68M
Liberty wealth management340.15K0.02%$115.00K
Weaver consulting group15.62K0.01%$35.46K
Virtu financial49.59K0.00%$17.00K
Tower research capital llc (trc)86.58K0.00%$29.35K
Two sigma securities102.02K0.00%$34.53K
Institutional & family asset management6.00K0.00%$2.03K
Group one trading46.75K0.00%$15.83K
Blackrock386.41K-$130.80K
Gsa capital partners llp---

Top Buyers

HolderShares% AssetsChange
Armistice capital7.92M0.03%7.92M
Geode capital management484.29K-127.24K
Vanguard group1.51M-109.65K
Two sigma securities102.02K0.00%102.02K
Tower research capital llc (trc)86.58K0.00%75.57K

Top Sellers

HolderShares% AssetsChange
Weaver consulting group15.62K0.01%-218.73K
Abner herrman & brock---145.50K
Gsa capital partners llp---111.23K
Blackrock386.41K--102.90K
Ikarian capital---90.24K

New Positions

HolderShares% AssetsChangeValue
Armistice capital7.92M0.03%7.92M$2.68M
Two sigma securities102.02K0.00%102.02K$34.53K
Lpl financial10.05K-10.05K$3.40K
Northwestern mutual wealth management161.00-161.00$55.00

Sold Out

HolderChange
Mark sheptoff financial planning-100.00
Corecap advisors-133.00
Westside investment management-200.00
Bnp paribas arbitrage, snc-364.00
St germain d j-500.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202437-26.00%10,822,353-10.37%154.37%10-52.38%9-
Jun 30, 2024504.17%12,075,121210.89%1851.82%2175.00%9-18.18%
Mar 31, 202448-4.00%3,884,1112.17%57.70%12-29.41%11-8.33%
Dec 31, 202350-12.28%3,801,493-17.96%88.05%17-32.00%12-
Sep 30, 202357-10.94%4,633,812-16.75%105.33%25-12-7.69%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv50.72K0.89%-20.02K
Fidelity Extended Market Index28.25K0.50%-186.00
Vanguard Institutional Extnd Mkt Idx Tr26.73K0.47%-
Fidelity Total Market Index9.56K0.17%-
Fidelity Series Total Market Index6.85K0.12%-233.00
NT Ext Equity Mkt Idx Fd - L5.32K0.09%-
BlackRock Extended Equity Market K62.75K0.08%-27.00
Extended Equity Market Fund K4.13K0.07%-57.00
Vanguard Instl Ttl Stck Mkt Idx Tr33.75K0.04%-
Spartan Extended Market Index Pool E2.22K0.04%186.00

Recent Insider Transactions


DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends


DateBuySell
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--
2023 Q31-

BCLI Ownership FAQ


Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 15.20%, followed by 9.04% insiders and 75.76% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 109.70%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Armistice capital (7.92M shares, 12.23%), Vanguard group (1.51M shares, 2.33%), and Geode capital management (484.28K shares, 0.75%). Together, they hold 15.31% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Armistice capital is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.03% of its assets in 7.92M Brainstorm Cell Therapeutics shares, valued at 2.68M$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 0.89% of its total shares outstanding invested in 50.72K Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools